HONG KONG – Chinese clinical-stage biotech Connect Biopharmaceuticals Ltd., of Suzhou, secured $55 million in a series B financing to move forward its two lead drug candidates, CBP-307 for treating ulcerative colitis and Crohn's disease and CBP-201 for treating atopic dermatitis, to the next stage.